Document registry — page 37
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low12 Sep 2023 -
Observational, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Sep 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier randomising 88 participants over 24 months. Primary result: Reductions were maintained during…
Moderate11 Sep 2023 -
Single-arm open-label, phase 3 study of Liraglutide in prediabetes and obesity over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Semaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low11 Sep 2023 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Sep 2023 -
Single-arm open-label, phase 3 study of Pramlintide in type 1 diabetes (adjunct) over open-label extension of the parent trial. The Institute holds no reported primary…
Very low11 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low10 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tesamorelin in lipodystrophy randomising 404 participants over 26 weeks. Primary result: Directionally…
Moderate08 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes randomising 411 participants over 16 weeks. Primary result: Glycaemic…
07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low07 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low07 Sep 2023 -
Phase 1 ascending dose, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary…
Very low06 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef over as stated in the parent protocol. The Institute holds no reported…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Sep 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low05 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Sep 2023 -
Observational, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary…
Very low04 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Ipamorelin in gastric emptying over in-hospital. Primary result: The programme did not proceed. The…
02 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low02 Sep 2023 -
Randomised crossover, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low02 Sep 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low29 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 1,961 participants over 68 weeks. Primary result: Mean change −14.9 %…
High27 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes randomising 3,297 participants over 104 weeks. Primary…
High27 Aug 2023 -
Single-arm open-label, phase 3 study of Semaglutide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low26 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low26 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Lixisenatide in cardiovascular and type 2 diabetes randomising 6,068 participants over median 25 months…
High21 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes randomising 388 participants over 30 weeks. Primary result: Reduction of…
High20 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low20 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low18 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity randomising 611 participants over 68 weeks. Primary result: Mean change −16.0 %…
High17 Aug 2023 -
Single-arm open-label, phase 2 study of Pramlintide in obesity over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low17 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Aug 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Exenatide in cardiovascular and type 2 diabetes randomising 14,752 participants over median 3.2 years…
High16 Aug 2023 -
Single-arm open-label, phase 3 study of SS-31 (elamipretide) in mitochondrial disease over open-label extension of the parent trial. The Institute holds no reported…
Very low16 Aug 2023 -
Randomised, double-blind, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 976 participants over 26 weeks. Primary result: Superior to…
High15 Aug 2023 -
Randomised crossover, phase 1 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Aug 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low15 Aug 2023 -
Observational, phase 3 study of Semaglutide in cardiovascular and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Aug 2023
page 37 of 41